Education
About Us
Working with TipRanks
Follow Us
Atossa Therapeutics, Inc. (GB:0HJ7)
:0HJ7
0HJ7 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsPositive topline data from the KARISMA-Endoxifen Phase 2 study demonstrated that low doses of (Z)-endoxifen significantly reduced mammographic breast density and was well tolerated.
Financial PerformanceCurrent valuation attractive with a BUY rating maintained and 12-month price target raised to $7.00, representing significant upside from the current share price.
Bears Say
Adverse EffectsThere were no significant adverse events between the placebo and 1 mg arms, while the 2 mg arm saw higher rates of hot flashes, night sweats, and vaginal discharge.
---
Options Prices
Currently, No data available
---
Ownership Overview
7.29% Insiders
8.06% Mutual Funds
0.41% Other Institutional Investors
75.17% Public Companies and Individual Investors
0HJ7 FAQ
What was Atossa Therapeutics, Inc.’s price range in the past 12 months?
Currently, no data Available
What is Atossa Therapeutics, Inc.’s market cap?
Currently, no data Available
When is Atossa Therapeutics, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Atossa Therapeutics, Inc.’s earnings last quarter?
Atossa Therapeutics, Inc. released its earnings results on Nov 12, 2024. The company reported -$0.06 earnings per share for the quarter, the consensus estimate of -$0.06 by $0.
Is Atossa Therapeutics, Inc. overvalued?
According to Wall Street analysts Atossa Therapeutics, Inc.’s price is currently Undervalued.
Does Atossa Therapeutics, Inc. pay dividends?
Atossa Therapeutics, Inc. does not currently pay dividends.
What is Atossa Therapeutics, Inc.’s EPS estimate?
Atossa Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Atossa Therapeutics, Inc. have?
Currently, no data Available
What happened to Atossa Therapeutics, Inc.’s price movement after its last earnings report?
Atossa Therapeutics, Inc. reported an EPS of -$0.06 in its last earnings report, expectations of -$0.06. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Atossa Therapeutics, Inc.?
Currently, no hedge funds are holding shares in GB:0HJ7
---
Atossa Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.00 (― Downside)
$7.00 (― Downside)
Blogger Sentiment
Bullish
GB:0HJ7 Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-38.33%
12-Months-Change
Fundamentals
Return on Equity
-31.30%
Trailing 12-Months
Asset Growth
-21.85%
Trailing 12-Months
Company Description
Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests. The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65. The ArgusCYTE Breast Health Test offers information to help inform breast cancer treatment options and to help monitor potential recurrence. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.
---
0HJ7 Stock 12 Month Forecast
Average Price Target
$7.00
Bioline RX Ltd Sponsored ADR
―
Cyclacel Pharmaceuticals
―
Immunic
―
Affimed
―
Marker Therapeutics
―
Best Analysts Covering 0HJ7
1 Year
1 Year Success Rate
5/12 ratings generated profit
1 Year Average Return
+0.71%
assigned a buy rating 3 months ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 41.67% of your transactions generating a profit, with an average return of +0.71% per trade.
---